Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.34 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22883496 | 0.87 | KDM4E (0.38) | KDM4ETAS1R3TAS1R1TLR7 | |
| SCHEMBL22883249 | 0.84 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1TLR7LMNA | |
| SCHEMBL22034185 | 0.80 | KDM4E (0.44) | KDM4ETAS1R3TAS1R1TLR7 | |
| SCHEMBL18510815 | 0.78 | KDM4E (0.41) | KDM4ETAS1R3TAS1R1TLR7LMNA | |
| SCHEMBL18521376 | 0.78 | KDM4E (0.44) | KDM4ETAS1R3TAS1R1TLR7 | |
| SCHEMBL26534550 | 0.76 | KDM4E (0.38) | KDM4EMEN1TSHRKMT2ATAS1R3 | |
| SCHEMBL22883489 | 0.74 | KDM4E (0.37) | KDM4ETAS1R3TAS1R1 | |
| SCHEMBL22883454 | 0.73 | MEN1 (0.48) | KDM4EMEN1KMT2ATAS1R3TAS1R1 | |
| SCHEMBL22401420 | 0.73 | KDM4E (0.45) | KDM4ETAS1R3TAS1R1ALDH1A1LMNA | |
| SCHEMBL21637008 | 0.73 | KDM4E (0.45) | KDM4EMEN1KMT2AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009630-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009630-A1 | CYCLIC DINUCLEOTIDES AS STING AGONISTS | STING1, CGAS, IFNAR1 | KDM4E 4282/4885MEN1 307/4885TSHR 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.